MedWatch

Biotech company in crisis after just one year - candidate failed

Newly-founded ROS Therapeutics' lead candidate showed disappointing pre-clinical results. The company's future now hangs by a thread.

Foto: ROS Therapeutics

Already before it really got off the ground, the young Danish biotech company ROS Therapeutics is undergoing a crisis.

The company had developed a new version of the anti-rheumatic drug methotrexate and dreamed of stealing market shares from Abbvie's best-seller Humira. However, the candidate showed disappointing pre-clinical results.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier